. 2020 Aug 12;9(9):864–873. doi: 10.1530/EC-20-0292
This work is licensed under a Table 1.
Baseline characteristics of the study cohort.
| Case no. | Sex | Age at start of therapy | Primary tumor | Indication for PRRT | Site of metastasis | Secretory status | Number of PRRT cycles | Cumulative dose of PRRT (GBq) | Follow up (in months) | Baseline meana SUVmax (Krenning score) | Previous therapy | Mutation/amino acid | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Surgery | EBRT | ||||||||||||
| 1 | M | 14 | PCC + PNET | Progressive, inoperable | NA | S | 5 | 25 | 32 | 5.7 (II) | + | − | VHL (Exon:3)/p.(Arg167Trp |
| 2 | M | 27 | PCC + sPGL + PNET | Progressive, metastasis (metachronous) | Liver | S | 3 | 10 | 21 | 25.5 (IV) | + | − | VHL (Exon:1)/ p.(Tyr98Ser) |
| 3 | F | 18 | sPGL | Progressive, metastasis (metachronous) | Skeletal, lung, LN | S | 6 | 37 | 62 | 28.5 (IV) | − | − | SDHB (Exon:4)/p.Gly96Asp |
| 4 | M | 38 | HNPGL + sPGL | Inoperable | NA | S | 6 | 40 | 35 | 106 (IV) | − | − | SDHD (Exon:4)/p.Ser8LysfsTer6 |
| 5 | M | 59 | PCC | Progressive, metastasis (metachronous) | Lung, liver, LB | S | 3 | 19 | 17 | 12.8 (III) | + | − | Negative |
| 6 | F | 22 | PCC + PNET |
Progressive inoperable | NA | S | 3 | 19 | 27 | 40 (IV) | + | − | ND |
| 7 | F | 39 | sPGL | Progressive, metastasis (metachronous) | LN, LB | S | 2 | 11 | 54 | 7.6 (II) | + | − | ND |
| 8 | F | 37 | PCC | Progressive, metastasis (metachronous) | Skeletal, liver | S | 4 | 28 | 15 | 17.4 (III) | + | − | ND |
| 9 | M | 49 | sPGL (bladder) |
Progressive, metastasis (synchronous) |
Skeletal | S | 2 | 15 | 11 | 35.5 (IV) | + | − | ND |
| 10 | M | 44 | sPGL | Inoperable + metastasis (synchronous) | Skeletal | NS | 1 | 6 | 11 | 61.5 (IV) | + | + | ND |
| 11 | M | 39 | HNPGL | Inoperable + metastasis (synchronous) | Skeletal, liver, lymph node | NS | 5 | 30 | 52 | 41.7 (IV) | − | + | ND |
| 12 | F | 18 | HNPGL | Inoperable + metastasis (synchronous) | Lung | NS | 6 | 35 | 36 | − | − | − | ND |
| 13 | F | 41 | HNPGL | Inoperable | NA | NS | 6 | 40 | 34 | 138 (IV) | + | − | ND |
| 14 | F | 25 | HNPGL | Inoperable | NA | NS | 5 | 34 | 26 | 254 (IV) | + | − | ND |
| 15 | F | 42 | HNPGL | Inoperable + metastasis (synchronous) | Skeletal | NS | 5 | 32 | 27 | 57 (IV) | − | + | ND |
aFor a patient having one lesion, single lesion SUVmax, and more than one lesion mean SUVmax were calculated.
EBRT, external beam radiotherapy; F, female; HNPGL, head and neck paraganglioma; LB, local bed; LN, lymph node; M, male; NA, not applicable; ND, not done; NS, non-secretory; PCC, pheochromocytoma; PNET, pancreatic neuroendocrine tumor; S, secretory; sPGL, sympathetic paraganglioma.